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Abstract: The combined clinical and molecular heterogeneity of
prostate cancer necessitates the use of prognostic, predictive, and di-
agnostic biomarkers to assist the clinician with treatment selection.
The pathologist plays a critical role in guiding molecular biomarker
testing in prostate cancer and requires a thorough knowledge of the
current testing options. In the setting of clinically localized prostate
cancer, prognostic biomarkers such as Ki-67 labeling, PTEN loss or
mRNA-based genomic signatures can be useful to help determine
whether definitive therapy is required. In the setting of advanced dis-
ease, predictive biomarkers, such as the presence of DNA repair de-
ficiency mediated by BRCA2 loss or mismatch repair gene defects,
may suggest the utility of poly-ADP ribosylase inhibition or immune
checkpoint blockade. Finally, androgen receptor–related biomarkers
or diagnostic biomarkers indicating the presence of small cell neuro-
endocrine prostate cancer may help guide the use of androgen receptor
signaling inhibitors and chemotherapy. In this review, we examine the
current evidence for several prognostic, predictive and diagnostic tis-
sue-based molecular biomarkers in prostate cancer management. For
each assay, we summarize a recent survey of the International Society
of Urology Pathology (ISUP) members on current testing practices
and include recommendations for testing that emerged from the ISUP
Working Group on Molecular Pathology of Prostate Cancer and the
2019 Consultation Conference on Molecular Pathology of Urogenital
Cancers.
Key Words: prostate cancer, biomarkers, PTEN, Ki-67, AR,
neuroendocrine, homologous recombination, mismatch repair
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Prostate cancer is a clinically and molecularly hetero-genous disease with a wide spectrum of management
strategies tailored to its highly variable clinical outcomes.
Once diagnosed, these features make it essential to have
accurate prognostic, predictive and diagnostic biomarkers
to assist the clinician in treatment selection. Beyond ac-
curate diagnosis, grading and staging, the pathologist
plays a key role in guiding subsequent tissue-based mo-
lecular biomarker testing in prostate cancer and requires a
thorough knowledge of the available assays, their appli-
cation in specific disease states and the evidence for their
clinical utility. In the localized setting, prostate cancer
clinical management options include active surveillance
(AS), radical prostatectomy and radiation therapy, and
prognostic biomarkers can assist in determining whether
definitive therapy is required. Historically, treatment of
metastatic prostate cancer has largely been independent
of histology or biomarkers, limiting most pathologists’
experience with histologic assessment of metastatic
From the Departments of *Pathology; †Oncology; ‡Urology, Johns
Hopkins University, Baltimore, MD; §Department of Pathology,
Urology and Rogel Cancer Center, University of Michigan Medical
School, Ann Arbor, MI; ∥Department of Pathology and Laboratory
Medicine, University of Calgary Cumming School of Medicine and
Alberta Public Labs, Calgary, AB; ¶Laboratory Medicine Program,
University Health Network, Toronto, ON, Canada; #Department of
Pathology and Laboratory Medicine, Indiana University School of
Medicine, Indianapolis, IN; **Department of Oncology and Pathol-
ogy, Karolinska Institute, Solna, Sweden; ††Department of Pathol-
ogy, University Hospital Bonn, Bonn, Germany; ‡‡Department of
Laboratory Medicine, University of Washington, Seattle, WA;
§§Department for Biomedical Research, University of Bern and Bern
Center for Precision Medicine, Bern; and ∥∥Institute of Pathology,
University Hospital Basel, Basel, Switzerland.
T.L.L. has received research funding from Ventana/Roche and Ge-
nomeDx Biosciences. S.A.T. has served as a consultant for and re-
ceived honoraria from Janssen, AbbVie, Sanofi, Almac Diagnostics,
and Astellas/Medivation. S.A.T. has had sponsored research agree-
ments with Astellas/Medivation and GenomeDX. S.A.T. is an equity
holder in, a prior consultant for, and current employee of Strata
Oncology. M.A.R. has received research support from Sanofi-Aven-
tis, Millennium Pharma, Eli-Lilly and Janssen. M.A.R. has served as
a consultant or received honoraria from ROCHE and Novartis.
T.A.B. has received research funding from GenomeDX. L.B. has
received research funding from Ventana/Roche. G.K. has received
research funding from Astellas Pharma and has received honoraria
from Astellas, Roche and Janssen. The remaining authors have dis-
closed that they have no significant relationships with, or financial
interest in, any commercial companies pertaining to this article.
Correspondence: Tamara L. Lotan, MD, 1550 Orleans St., Baltimore,
MD 21231 (e-mail: tlotan1@jhmi.edu).
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
SPECIAL ARTICLE
Am J Surg Pathol  Volume 44, Number 7, July 2020 www.ajsp.com | e15
Copyright r 2020 Wolters Kluwer Health, Inc. All rights reserved.
prostate cancer or guidance of appropriate tissue-based
biomarker testing. More recently, recognition of both
AR signaling–dependent and AR signaling–independent
castration-resistant prostate cancer (CRPC) (the latter
often representing small cell neuroendocrine [NE] carci-
noma), potentially targetable subtypes of CRPC (eg, ho-
mologous recombination-deficient and mismatch repair
[MMR]-deficient), as well as increasing therapeutic op-
tions (eg, chemotherapy, AR signaling inhibitors, targeted
therapies and immunotherapy) have driven intense inves-
tigation of diagnostic and predictive biomarkers that can
be used to guide CRPC management.1
In this review, we examine the current evidence for
several prognostic, predictive and diagnostic tissue-based
molecular biomarkers in prostate cancer management. For
each assay, we summarize a recent survey of the International
Society of Urology Pathology (ISUP) members on current
testing practices. This survey included data from 256 ISUP
members (all pathologists), 75% of whom have been in
practice for >10 years (including residency), with the ma-
jority (62%) working in university/academic settings. In ad-
dition, for each assay, we include recommendations for testing
that emerged from the ISUP Working Group on Molecular
Pathology of Prostate Cancer and the 2019 Consultation
Conference on Molecular Pathology of Urogenital Cancers.
PROGNOSTIC BIOMARKERS IN LOCALIZED
PROSTATE CANCER
Prognostic biomarkers estimate the overall likelihood
of an adverse clinical outcome, regardless of the specific
therapeutic setting. These assays may be used to guide
clinical management of localized prostate cancer, where AS
may be a reasonable option, or as decision support tools
after radical prostatectomy where adjuvant radiation and
hormonal therapy may be efficacious in aggressive disease.
Countless single markers have been claimed to have prog-
nostic utility in prostate cancer during the past decades, yet
none has survived the valley of death on the way to the
routine clinical application until now.2 The proliferation
marker Ki-67 and the tumor-suppressor protein, PTEN have
emerged as the most promising single immunohistochemical
(IHC) markers based on accumulated published evidence at
this point of time. In addition, several RNA-based com-
mercial genomic assays can provide reproducible prognostic
information by expression profiling and are listed by the
guidelines of the National Comprehensive Cancer Network
(NCCN) as an option for better patient stratification. Despite
considerable progress in biomarker validation, systematic use
of prognostic biomarkers in prostate cancer is currently not
recommended by urological societies. Thus, urologists and/or
oncologists may drive the selection and use of the tests
depending on institutional policy.
Ki-67
Background
Ki-67 is a protein encoded by the MKI67 gene and
was first described in Hodgkin lymphoma as an antigen
that is highly expressed in cycling cells but absent in
resting G0-phase cells.3 Although the biological function
of Ki-67 remains poorly understood, Ki-67 has been
shown to regulate cell cycle progression by different
mechanisms.4,5 Ki-67 has become the prototype IHC “cell
proliferation marker” and has extensively been used in
pathology for diagnostic or prognostic purposes across
different tumor types including breast cancer, NE tumors,
lymphomas, and sarcomas. The fraction of Ki-67 positive
tumor cell nuclei is commonly referred to as the Ki-67
labeling index (LI) or Ki-67 score. In breast cancer, Ki-67
LI is used to help stratifying patients for neoadjuvant
chemotherapy and it serves as a key diagnostic criterion
for grading gastrointestinal NE tumors according to the
criteria of the World Health Organization (WHO).6,7
Evidence
Accumulated published evidence have also consistently
shown a prognostic role of Ki-67 in localized prostate cancer,
as recently summarized in a meta-analysis of 21 selected
studies between 1996 and 2014 including 5419 patients with
localized prostate cancer.8 A prognostic effect was observed
across all endpoints including biochemical recurrence (BCR)-
free survival, disease-specific survival, metastasis-free survival,
and overall survival. An independent prognostic role of Ki-67
LI has also been emphasized in a subsequent large multi-
institutional study on over 1000 radical prostatectomy
specimens.9 The authors used tissue microarrays (TMA) with
each surgical specimen being represented by 3 TMA cores at
a diameter of 1 mm, thus mimicking transrectal ultrasound–
guided core biopsies. Although TMA studies are practical for
efficient biomarker studies, analysis of Ki-67 LI on core bi-
opsies is more relevant since they better reflect clinical practice
in routine pathology laboratories. In fact, several studies
showed that the independent prognostic value of Ki-67 also
holds true in core biopsy specimens.10–12 Prospectively as-
sessed Ki-67 LI in preoperative biopsies with low-volume or
low-grade (Gleason score <7) prostate cancer in routine
clinical practice was shown to be an independent prognostic
factor in terms of postoperative biochemical-free recurrence.13
In a recent retrospective analysis of 756 conservatively man-
aged patients, Ki-67 LI on biopsy grade group 1 and 2 prostate
cancer also emerged as an independent prognostic marker
of tumor-specific survival.12 These studies suggest that
Ki-67 LI has high promise in helping to better select patients
for AS. In fact, high Ki-67 LI has been shown to be in-
dependently associated with a switch to active treatment after
AS when tested on TMAmade from pre-AS prostate biopsies
from 60 patients.14
Aside from the lack of prospective clinical validation,
there are several postanalytical hurdles explaining why Ki-67
testing has not yet widely entered clinical practice. These in-
clude lack of a consensus on the optimal threshold to define
low and high proliferation, different scoring procedures and
interobserver variability in reading IHC slides. Important
lessons can be learned from the breast cancer field in this
respect. Despite major efforts in harmonizing Ki-67 analysis
in breast cancer and recommendations on how to evaluate
Ki-67 LI, interlaboratory variability in Ki-67 evaluation
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has remained substantial even in the most experienced
laboratories.15–17 Nevertheless, a large meta-analysis showed
the independent prognostic value of Ki-67 LI for overall
survival, and a cutoff of ≥25% was proposed as most ap-
propriate for prognostic stratification in breast cancer.18 Be-
cause of its established clinical value, wide availability and
low costs relative to commercial genomic signatures, Ki-67
testing of breast cancer has been endorsed in European
practice guidelines.19,20 However, given the evident variability
between laboratories, it was noted that scores should be in-
terpreted in the light of local laboratory values to define Ki-
67 LI as clearly low (eg, <10%) or clearly high (eg,
>30%).19,20 According to meta-analyses, the reported median
Ki-67 LIs in prostate cancer are lower than in breast cancer
(6.1% vs. 14%).8,18 Thus, the most appropriate threshold for
Ki-67 LI in prostate cancer appears to lie between 5% and
10%.8,9,12 Since Ki-67 LI is a continuous variable, there will
be an inevitable intermediate gray zone between a clearly low
(eg, <5%) and a clearly high Ki-67 LI (eg, >15%) (Fig. 1).
Other technical details remain to be clarified for Ki-67
scoring of prostate cancer, including the required minimum
number of tumor cells and the mode of evaluation (eg, whole
area vs. hotspots and counting vs. visual estimates).
Automated image analysis for Ki-67 scoring is feasible and
might play an increasing role in standardizing and facilitating
Ki-67 scoring, although it has not yet been proven to be
superior to visual evaluation.9,12,21,22
Discussion for Ki-67
In the ISUP survey preceding the Consultation Con-
ference, the majority of respondents indicated that they did
not currently recommend (58%) or use (67%) any in situ
prognostic biomarkers in radical prostatectomy samples.
Given that the final Grade Group, pathologic stage and other
clinical-pathologic parameters in the radical prostatectomy
sample are highly prognostic, this seems a reasonable ap-
proach. In addition, none of these biomarkers have been
directly tested for prognostic value in the setting of adjuvant
or salvage radiation therapy, which is the clinical context in
which they would be used postsurgery. In the context of
prostate core biopsies, survey respondents were more evenly
divided about whether prognostic markers such as Ki-67 and
PTEN could be recommended. In this setting, 46% of re-
spondents answered that prognostic biomarkers could not be
currently recommended in routine practice, while 45% felt
that they could be helpful in decision-making regarding AS
versus definitive therapy. Among in situ biomarkers, Ki-67
and PTEN were the most commonly used in core biopsies,
however <10% of respondents reported using either bio-
marker overall.
According to the accumulated evidence, Ki-67 LI
appears as a robust prognostic marker in prostate cancer
that can be advocated for use in clinical practice. Ki-67 LI
might be particularly useful in patients considered for AS.
However, further efforts are needed to improve the
standardization of Ki-67 scoring and to validate the
prognostic value in prospective studies. In addition, Ki-67
LI testing, which is inexpensive and globally established
in pathology laboratories, needs to be compared against the
more expensive and centrally tested commercial genomic as-
says that measure proliferation signatures, as described be-
low. For the formal recommendations of the Working




Among the common molecular alterations observed
in primary prostate cancer, PTEN loss has emerged as one
FIGURE 1. Ki67 LI in Grade Group 1 prostate cancer core biopsies. A, High LI (∼15%). B, low Ki-67 LI (<5%).
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of the more robust prognostic biomarkers. The PTEN
protein functions primarily as a lipid phosphatase, oppos-
ing the oncogenic PI3K/AKT signaling cascade. In primary
prostate cancer, PTEN is lost most commonly by genomic
deletion, though genomic rearrangements and more rarely,
truncation mutations leading to PTEN inactivation have
been described.23 Accordingly, fluorescence in situ hybrid-
ization (FISH) assays to detect PTEN deletions or re-
arrangements, as well as IHC assays to detect PTEN
protein loss, are the most common assays utilized to as-
certain PTEN status, and demonstrate a high level of
concordance in numerous studies23–26 (Fig. 2). As with
many prognostic biomarkers including Ki-67, the frequency
of PTEN loss increases with increasing Grade Group as
well as pathologic stage,27 thus the prevalence of PTEN loss
varies significantly between different cohorts. Among
surgically treated patients, most studies have identified
PTEN loss in ∼20% of prostate tumors, with the prevalence
FIGURE 2. PTEN IHC and PTEN FISH in primary prostate cancer samples. A, PTEN IHC loss is homogeneous in the sampled tumor,
with nerves providing an internal positive control (box depicts area examined by FISH in B). B, PTEN gene loss by FISH is assessed
by examining the PTEN probe (orange) and centromere 10 (CEN10) probe counts (red) in tumor cells. In this sample, PTEN loss is
homozygous in tumor cells and PTEN is intact in nearby Schwann cell nuclei (box depicts area examined at higher magnification in
C). C, Schwann cell nuclei show intact PTEN (arrow) while adjacent tumor nuclei (arrowhead) have homozygous PTEN loss. D,
PTEN IHC loss is heterogenous in the sampled tumor, with stromal cells providing an internal positive control (box depicts area
examined by FISH in E). E, In the region of PTEN protein loss, PTEN loss is homozygous in tumor cells and PTEN is intact in nearby
stromal cells (box depicts area examined at higher magnification in F). F, Stromal cell nuclei show intact PTEN (arrow) while
adjacent tumor nuclei (arrowhead) have homozygous PTEN loss. G, PTEN IHC loss is homogeneous in the sampled tumor, with
stromal cells providing an internal positive control (box depicts area examined by FISH in H). H, PTEN loss is hemizygous in tumor
cells (box depicts area examined at higher magnification in I). I, Tumor nuclei have hemizygous PTEN loss.
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rising to 40% among metastatic tumors.23 Though PTEN
loss most commonly occurs in the primary tumor with
identical PTEN status across metastases within a given
patient,28 PTEN deletion occurs subsequent to some other
alterations, such as ERG gene rearrangement29,30 and is
subclonal or heterogenous in up to 40% of primaries with
underlying PTEN loss.23,31
Evidence
Most studies examining PTEN as a prognostic bio-
marker have focused on surgically treated patients and ex-
amined the clinical outcome of BCR (rising prostate-specific
antigen [PSA] serum levels). In the majority of these studies,
tumors with PTEN loss (either by FISH or IHC) have had a
statistically significant increase in the hazard ratio (HR) of
BCR compared with tumors with intact PTEN (with the HR
typically around 1.2 to 1.5 after adjusting for Grade Group
and stage).32–35 Cases with hemizygous genomic deletion
generally have outcomes somewhat intermediate between
cases with intact PTEN and homozygous deletion.32 Sim-
ilarly, cases with heterogenous or subclonal protein loss
typically have worse outcomes than those with intact PTEN
but somewhat better outcomes than patients with clonal or
homogenous PTEN protein loss.24,26 Though studies of pa-
tients treated by radiation therapy have been fewer in
number, PTEN loss is generally similarly prognostic in these
cohorts as well.36,37
Despite the abundance of studies using this outcome
measure, it is widely accepted that BCR is a suboptimal
surrogate for metastasis and death. Thus most prognostic
biomarkers must be tested for their association with
metastatic or lethal prostate cancer.38 Given that the du-
ration of follow-up must be quite extensive to detect lethal
events in surgically treated prostate cancer, many early
studies of PTEN and lethal prostate cancer were per-
formed in nonsurgical cohorts, including transurethral
resection of the prostate or needle biopsy samples from
patients who were conservatively managed. In these co-
horts, PTEN has remained highly significant as a prog-
nostic biomarker.39,40 To date, there have only been 2
large studies of PTEN in surgical cohorts with metastasis
or death as an outcome measure, including 1 population-
based cohort and 1 single-institution cohort.41,42 In both
of these, PTEN loss remained significantly associated with
the risk of lethal prostate cancer, even after adjusting for
clinical-pathologic variables, with HR between 2 and 5.
While it is clear that PTEN is prognostic on its own,
there has also been great interest in discerning whether PTEN
loss may be more clinically significant in specific molecular
contexts. Rearrangements involving the ERG gene are
among most common structural variants in prostate cancer43
and while not associated with poor outcomes by themselves
in surgically treated cohorts,44–46 ERG-rearranged prostate
tumors are more likely to have PTEN loss than those that
lack this rearrangement.30,31,47–52 Accordingly, animal studies
have suggested that there may be a synergistic effect of ERG
expression and PTEN loss on prostate cancer
progression.48,49,53 In humans, using the endpoint of BCR
in surgically treated cohorts, most studies examining the
potential interaction between PTEN and ERG have had
mixed results, with the largest studies indicating there is no
interaction between the 2 alterations.47,52 However, using the
outcome of prostate cancer-specific mortality, several studies
have found that PTEN loss in the absence of ERG gene
rearrangement has worse outcomes compared with PTEN
loss occurring with ERG gene rearrangement. In both con-
servatively managed,40,51 as well as surgical cohorts,40,41
PTEN deletion or loss was strongly associated with an in-
creased risk of lethal prostate cancer among ERG-negative,
but not among ERG-positive tumors, though not all studies
have formally tested the statistical interaction. To date, it
remains unclear why these data in humans differ as a function
of the clinical outcome analyzed, and why they diverge so
dramatically from murine models.
Because of its strong correlation with the pathologic
grade, PTEN loss is perhaps most useful as a prognostic bi-
omarker in the setting of prostate transrectal ultrasound–
guided core biopsies. In this context, the pathologic stage is
unknown and Grade Group may be underestimated due to
insufficient sampling. Thus, patients with PTEN loss in Grade
Group 1 tumors at biopsy have a nearly 3-fold increase in the
likelihood of upgrading to Grade Group 2 or higher at radical
prostatectomy.54 Similarly, PTEN loss in Grade Group 2
biopsies is associated with an increased risk of nonorgan
confined disease and BCR after radical prostatectomy.55 Fi-
nally, at least one study has demonstrated that PTEN loss in
core biopsies is associated with the development of metastasis,
prostate cancer–specific mortality and CRPC in surgically
treated patients.56 While these studies suggest that PTEN loss
may be useful in identifying patients who should avoid AS
only 2 studies have directly tested this biomarker within AS
cohorts. In the largest study to date, PTEN loss was asso-
ciated with a 2.6-fold increase in upgrading on repeat
biopsy.57 In another case-control study, PTEN loss was less
common among patients who remained on AS after 8 years
of follow-up compared with patients who had rapid or sig-
nificant upgrading, though this difference did not reach sta-
tistical significance in this relatively small case-control study.58
As PTEN and other prognostic biomarkers undergo
extensive validation, it is essential to do comparison studies
between markers to nominate only the best and most
economical assays for clinical use. To date, only a few
studies performing head-to-head comparisons of PTEN
and RNA-based biomarkers (described in more detail be-
low) have been published. Two of these studies have fo-
cused on surgical cohorts, with BCR as the outcome and
have demonstrated that when PTEN and Oncotype Dx
Genomic Prostate Score (GPS) or the Prolaris Cell Cycle
Proliferation (CCP) score are both included in multi-
variable models, PTEN is no longer significantly asso-
ciated with risk of recurrence.59,60 However, PTEN and the
Prolaris CCP assay performed comparably when meta-
stasis and death were used as clinical outcomes and the
concordance indices were formally compared for associa-
tion with this outcome.42 Of note, none of these studies
included a cost-benefit analysis, which is essential given the
difference in cost between IHC assays (a few hundred
dollars) and the RNA-based assays (a few thousand
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dollars) (Table 1). In addition, none of these studies were
performed in the context of biopsy samples, which is the
clinical setting where the biomarker testing would likely
take place. It is clear that additional direct comparison
studies are required to aid in the selection of the optimal
tissue-based prognostic biomarker(s).
Discussion and Recommendations for PTEN
and Ki-67
Taken together, the Working Group felt that current
evidence supports the following recommendations:
 Ki-67 LI and PTEN are potentially useful prognostic
biomarkers in the subset of Grade Group 1 (and/or Grade
Group 2) prostate cancer biopsies where the clinician is
seeking to determine whether the patient is eligible for AS.
 In this context, high Ki-67 LI or PTEN loss would be
one factor (among several) suggesting that the patient
should seek definitive treatment, while intact PTEN
would not be an informative result in this regard.
 Testing could be recommended for the single highest
grade/highest tumor volume core, with the option to
test additional cores, based on results of recent studies
suggesting that this may better capture overall hetero-
geneity and cases with subclonal PTEN loss.61
 This testing could be done by IHC (for Ki-67 and
PTEN) and/or FISH (for PTEN) as determined by the
pathologist.
However, while Ki-67 and PTEN remain among the
most promising prognostic molecular biomarkers studied to
date, the Committee agreed that additional dedicated studies of
AS populations are warranted before widespread adoption.
mRNA-BASED GENOMIC SIGNATURES
Background
mRNA-based signatures have been gaining traction in
recent years as new methods to aid in prognostication and
potential therapy response in patients with localized prostate
cancer. In the context of newly diagnosed prostate cancer, such
tests may add to current clinical-pathologic prognosticators and
may be useful for further refining risk stratification.62–64 More
recently, the applicability of such tests has also been extended
to AS cohorts.65,66 In the context of surgically treated patients,
some of these assays aim to answer questions related to com-
plex postsurgical management, such as whether patients with
adverse pathology on radical prostatectomy require salvage
radiotherapy or may safely avoid adjuvant radiation.67,68
Evidence
The best-studied RNA-based tests available commer-
cially for clinical use include Prolaris (Myriad Genetics),
Oncotype Dx (Genomic Health), and Decipher (Ge-
nomeDX Biosciences). Prolaris measures expression levels of
a panel of 31 CCP genes by reverse transcriptase-polymerase
TABLE 1. Common Example of Commercial mRNA-based Tests Available Clinically
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AUA indicates American Urological Association.
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chain reaction (RT-PCR) (Table 1). It was initially validated
to determine the risk of death from prostate cancer in a
cohort of conservatively managed patients using core biopsy
specimens.62 However subsequent studies expanded its use to
cohorts of surgically treated and radiation-treated patients,
where the CCP score is associated with BCR when measured
in the core biopsy.69,70 Finally, a few studies have validated
this assay using radical prostatectomy specimens, where
higher CCP is associated with risk of BCR and metastasis71
and could potentially support decision-making for use of
adjuvant therapies in this setting. To date, CCP has not been
studied in an AS population.
Similar to CCP, Oncotype Dx GPS is an RT-PCR
based assay that measures expression levels across a 17
gene panel including stromal response, androgen signal-
ing, cellular organization, and proliferation genes.63 On-
cotype Dx GPS has predominantly been validated in
biopsy samples from patients who were subsequently
surgically treated, where GPS is associated with increased
risk of adverse pathology at radical prostatectomy that
adds to the concordance index of the Cancer of the
Prostate Risk Assessment (CAPRA) clinical-pathologic
risk classifier.72 In addition, Oncotype Dx GPS has more
recently been evaluated for utility in biopsies from patients
on AS who underwent radical prostatectomy, where it was
associated with a higher risk of adverse pathology and
BCR.66 Finally, the Decipher genomic classifier includes
22 genes where expression is measured by high-density
Affymetrix microarrays.64 This test has been most ex-
tensively validated using radical prostatectomy tissue for
the purpose of predicting the risk of metastasis and as-
sisting with clinical decision-making surrounding the use
of adjuvant radiation and hormonal therapy.73–75 More
recent studies have examined the Decipher classifier in the
context of core biopsies.76 Though not yet reported in AS
populations, at least one study in men who were candi-
dates for AS found that Decipher improved on CAPRA
risk assessment if the conventional cutoff point was
lowered.63,65
Although considerable progress has been made to
date, moving forward, it is clear that prospective studies
testing these RNA-based assays in actual AS cohorts will
be required. In addition, future studies should focus on
validating them in conjunction with updated pathologic
Grade Groups and newer grading initiatives, such as
reporting of percentages of Gleason pattern 4 tumor and/
or the presence of cribriform Gleason 4 pattern, which
may add additional prognostic value.77 Though a few cost-
effectiveness studies have emerged recently, additional studies
are required before widespread adoption of these costly tests
can be recommended.78
Given that prostate cancer is a heterogenous disease
that is often multifocal in nature, studies evaluating the
reliability of RNA-based tests to inform on unsampled or
adjacent higher Grade Group tumor foci are needed.79
Unsurprisingly, in a recent study, derived RNA-based
tests failed to predict the presence of unsampled higher
grade foci in the context of multifocal disease when they
are performed on lower Grade Group foci.80 This high-
lights a global issue for all molecular tests performed on
biopsy tissue in prostate cancer, and additional studies are
necessary to determine the best ways to mitigate the risks
of undersampling for tissue-based biomarker assays.
Certainly the advent of multiparametric magnetic reso-
nance imaging–guided biopsies has the potential to im-
prove sampling in prostate cancer and prospective studies
combining molecular testing with image-guided biopsies
are needed.
Discussion and Recommendations for mRNA-
based Genomic Signatures
The ISUP survey documented that close to 60% of
practicing pathologists have never used RNA-based tests
on core biopsy specimens and the majority of such tests
are performed after clinician requests. This may be due to
the fact that there is commercial marketing of these tests
directly to the urologists. In addition, > 70% of patholo-
gists reported that they do not perform such tests in the
setting of radical prostatectomy.
The working group felt that RNA-based genomic
signatures are of potential benefit in the biopsy and radical
prostatectomy settings, with careful attention to what test
is ordered for which indication based on previous vali-
dation studies for specific tests.81 However, the potential
for undersampling remains a major concern for all tissue-
based tests and future clinician input may be useful to
shape any additional definitive recommendations given
that clinicians order the majority of these assays.
 Genomic signatures are of potential benefit in providing
additional information regarding progression risk for
prostate cancer in the AS and postradical prostatec-
tomy settings. However, they would do so only if the
focus harboring the disease was adequately sampled
and not missed completely.
 The improvement in such signatures should be com-
pared with implementing robust pathologic assessment
and potential use of IHC biomarkers which needs
further validation
 Studies are needed to assess signatures performance in
relation to heterogeneity in needle biopsy samples and
to confirm the proper way of performing such tests (ie,
which biopsy to use vs. using multiple biopsies from
different foci, etc.)
Predictive Biomarkers
Predictive biomarkers estimate the chances of re-
sponse to specific therapy and cannot be distinguished
from prognostic biomarkers unless 2 different therapies
are compared for biomarker-positive and biomarker-
negative patients.82 Although there is interest in develop-
ing predictive biomarkers for the localized setting in
prostate cancer (eg, to determine whether patients benefit
more from radiation or surgical therapy), to date, predictive
biomarkers have largely been studied in the context of
metastatic disease. Despite their importance for precision
medicine, relatively few tissue-based predictive biomarkers
have been validated.
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DNA REPAIR DEFICIENCY
Background
One area of particular excitement in this area in
recent years has been in the field of DNA repair
deficiency.83 Sequencing efforts in metastatic prostate
cancer demonstrated a surprisingly high rate of genomic
alterations in genes involved in the homologous re-
combination DNA repair pathway—approaching 20% of
cases of advanced CRPC and including alterations in the
BRCA2, BRCA1, and ATM genes most commonly.84
Perhaps even more surprising was the fact that nearly half
of these advanced cases with homologous recombination
defects (HRD) had germline mutations in these genes,
comprising close to 10% of men with CRPC.84,85 The
nearly 2-fold enrichment in somatic HRD mutations in
metastatic compared with the primary disease86 strongly
suggested that these alterations could be associated with
the development of aggressive disease and a number of
subsequent studies have confirmed this hypothesis for
germline HRD.87–90 Germline alterations in BRCA2
and ATM are significantly more common in lethal com-
pared with indolent primary prostate cancer91 and asso-
ciated with grade reclassification in AS populations.92
Further, in aggressive histologic subsets of primary pros-
tate cancer (including ductal and intraductal prostate
cancer and primary Gleason pattern 5 disease) the prev-
alence of HRD mutations (both germline and somatic)
reaches or even exceeds that seen in metastatic disease in
recent studies.93–98
Evidence
Given the large number of studies of HRD as a
predictive biomarker in breast and ovarian cancer over the
last 2 decades, it is perhaps unsurprising that HRD mu-
tations are predictive for therapy response in metastatic
prostate cancer as well, at least in initial studies. As in
breast and ovarian carcinomas, CRPC cases with germline
HRD alterations have improved responses to platinum
chemotherapy in retrospective studies.99,100 Even more
exciting is the apparent specific response to poly-ADP ri-
bosylase (PARP) inhibitors among CRPC cases with
HRD mutations. In the phase II TOPARP-A trial, 88%
(12/14) of men with HRD responded to the PARP in-
hibitor olaparib.101 Based in large part on these results,
both olaparib and rucaparib have received “Breakthrough
Therapy” designation by the Food and Drug Admin-
istration (FDA) for priority review in CRPC. Recent re-
ports from the Triton2102 and GALAHAD103 trials have
also reported responses among patients with BRCA2
mutations and the biomarker-selected PROfound trial104
suggested that biomarker-selected HRD patients derive
more benefit from olaparib than enzalutamide or abir-
aterone in the setting of CRPC. Notably, however, these
trials and some retrospective studies105 have failed to
confirm responses among many cases with ATM muta-
tions, suggesting that not all HRD mutations are similarly
predictive for therapy response and highlighting the need
for a functional biomarker of HRD in prostate cancer.
Defects in the MMR pathway are also enriched in
metastatic compared with primary prostate cancer.
Pathogenic mutations in MMR genes are seen in up to
10% of CRPC cases, compared with <3% of primary tu-
mors if all Grade Groups are considered together.106–108
However, similar to HRD, MMR mutations are highly
enriched among primary tumors with aggressive histology,
including both ductal adenocarcinomas and primary
Gleason pattern 5 tumors as recently reported.93,109,110
Relative to HRD alterations, fewer of the MMR muta-
tions (∼20%) in prostate cancer are germline, though
prostate cancer is now understood to be enriched among
patients with Lynch syndrome.111,112 Though prostate
cancer has shown only rare responses to immunotherapy
in most trials (with programmed death-ligand 1 expression
in only 8% of primary tumors and 32% of CRPC113), re-
cent trials have demonstrated anecdotal responses among
patients with underlying MMR defects114 and the FDA
has approved pembrolizumab for use in all progressing
tumors with MMR defects or microsatellite instability
(MSI) based largely on data in colorectal carcinoma.115
Indeed, 2 small retrospective series in CRPC patients
documented responses to checkpoint blockade among 2 of
4 patients in one series116 and 6 of 11 patients in a second
series,108 though whether responses will be as durable as
those observed in colorectal cancers with MMR defects
remains unclear.
Discussion and Recommendations for DNA
Repair Deficiency Markers
In the ISUP survey preceding the conference, close
to 20% of respondents had tested BRCA1/2 mutation
status in tissue specimens of advanced prostate cancer in
the past year, while close to 30% had tested MMR protein
status. Currently, the NCCN guidelines for prostate can-
cer recommend germline testing in high-risk subsets of
patients with clinically localized prostate cancer, including
all patients with Grade Group 4 or higher tumors or pa-
tients with PSA of ≥ 20 ng/mL.117 In addition, germline
testing should be performed in all patients with the
metastatic disease if clinically indicated, with appropriate
genetic counseling. Currently, all metastatic patients
should also be offered somatic genomic testing of tumor
tissue for HRD and MMR defects if clinically indicated.
The panel agreed with these current recommendations and
additionally addressed the important questions of which
tissues should be tested and which genomic tests should be
performed as pathologists frequently face these issues. The
majority of DNA repair defects appear to be early driver
events based on studies to date,108,109 thus though the se-
quencing of metastatic tissues is preferred, where this tissue is
not available, testing of the primary tumor may be performed.
Defective MMR assessment may be performed via IHC for
MMR proteins (MSH2, MSH6, MLH1, and PMS2), which
appears specific for underlying genomic alterations, though
formal testing of sensitivity has not been performed in the
setting of prostate cancer. Importantly, polymerase chain
reaction–based MSI testing has been demonstrated to be
insensitive in prostate cancer compared with IHC and
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more extended MSI testing by next-generation sequenc-
ing assays.109,118 Thus, polymerase chain reaction–based
MSI testing should be performed in concert with IHC
and/or sequencing wherever feasible. Targeted sequenc-
ing assays may not detect inactivating rearrangements in
MMR genes, and thus should be paired with IHC assays
where there is suspicion for MMR defects based on the
high mutational burden or MSI.
Recommendations of the Working Group were the
following:
 In combination with appropriate genetic counseling,
germline panel testing for DNA repair gene alterations
should be offered (if clinically indicated) to patients with:
Localized Grade Group ≥ 4 tumors.
Any Grade Group with PSA ≥ 20.
Known metastatic disease.
 Somatic tumor DNA testing should be offered to all
patients with the known metastatic disease if clinically
indicated. It can be performed on metastatic tissue or, if
unavailable, primary tissue. Testing should include:
Defective MMR assessment via MMR IHC for
MSH2, MSH6, MLH1, PMS2 with or without MSI
testing and/or sequencing of MMR genes (and tumor
mutation burden estimate).
AND
Defective HR assessment via sequencing for BRCA1,




Metastatic prostate cancer is frequently treated initially
with anti-androgen therapy (either alone or in combination
with other agents), with most patients responding. Sub-
sequent progressive disease despite castrate levels of serum
testosterone is termed CRPC. Additional therapies directly
or indirectly targeting the androgen receptor (AR) signaling
are frequently used in CRPC and include agents designed to
block androgen synthesis (abiraterone) or direct AR antag-
onists (enzalutamide and apalutamide). Although initially
thought to be independent of AR signaling, CRPC usually
remains dependent on AR signaling, and AR is the most
frequently altered gene in CRPC.1,119 In addition to point
mutations and amplifications of AR, amplification of en-
hancers of AR signaling are also frequent, along with the
expression of AR splice variants that lack the ligand-binding
domain and result in constitutive activation.28,120–124
Evidence
Building from gene expression profiling studies in
cell lines showing increased AR expression in castration-
resistant models over 15 years ago,125 large scale genomic
studies have shown that at least 50% of CRPC harbor AR
mutations (hotspots) or amplifications, in addition to
amplifications of AR enhancers28,120,121,123,124 (Fig. 3A).
Such genomic AR alterations can also be detected in cell-
free DNA (cfDNA),126 and importantly are essentially
absent in untreated prostate cancer.121,125 In addition,
again based on discoveries from cell line models,
FIGURE 3. AR amplification and ARV7 expression in CRPC. A, FISH showing high-level AR amplification with tight clusters of red AR
signals and few green CEPX reference signals. B, IHC showing homogeneous nuclear ARV7 expression (rabbit monoclonal antibody
clone RM7; Dianova).
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expression of AR splice variants, most commonly ARv7,
have been frequently detected in CRPC.127 ARv7 and
other AR splice variant expression rates vary across
detection methodology (eg, RT-PCR, RNAseq, or IHC),
biospecimen (eg, tissue samples vs. circulating tumor cells
[CTCs]), and line of therapy1,120–122,127–131 (Fig. 3B).
Importantly ARv7 and other splice variants have also been
detected at least in low levels in both untreated prostate
cancer as well as benign prostate tissue.121,122
To date, tissue-based assessment of AR alterations,
including ARv7 expression, have not been shown to be
strongly prognostic or, more importantly, predictive in
CRPC.120,121,123 Of note, by a variety of methods, many
men with CRPC harbor clonal populations with distinct
AR alterations and varying AR signaling output, and
ARv7 expression is very common in tumors after
castration.28,122,132 Hence, in part due to the infrequency
of routine biopsy of CRPC metastases, ARv7 detection in
CTCs and AR amplifications in cfDNA are the most
clinically advanced AR-based molecular biomarkers.
In both retrospective and prospective studies, ARv7
detection in CTCs by both RT-PCR and IHC has been
shown to be prognostic with respect to AR signaling in-
hibitors in CRPC.130,131,133 ARv7 detection in CTCs by
IHC has also been shown to be predictive in a retro-
spective study, with patients who harbor ARv7-positive
CTCs showing benefit from taxane chemotherapy versus
AR signaling inhibitors.129 This IHC-based CTC test,
Oncotype Dx ARV7 Nucleus Detect Test, has received a
positive local coverage determination in the United States
for men with CRPC. AR amplifications by cfDNA have
also been shown to be strongly prognostic in multiple
retrospective clinical trials and prospective/retrospective
nontrial cohorts.126,132,134–139 Importantly, for both ARv7
in CTCs and AR amplifications in cfDNA, prospective
randomized trials incorporating these biomarkers dem-
onstrating their prognostic or predictive ability have not
been reported.128
Discussion and Recommendations for AR-related
Markers
The ISUP survey demonstrated that the vast ma-
jority of urologic pathologists have limited experience with
AR as a tissue or blood-based biomarker in advanced
prostate cancer. More than 80% of responding patholo-
gists have not used AR mutations, AR amplifications,
ARv7 expression or AR expression by IHC as a tissue-
based biomarker in CRPC in the past year. More than
half have never been asked by a clinician to order these
biomarkers, with 20% of responding pathologists report-
ing being asked in <1% of cases. Likewise, > 90% report
their institution does not provide ARv7 testing from liquid
biopsies to predict response to AR signaling inhibitors.
On the basis of the above, the following recom-
mendations were made by the Working Group:
 At present, tissue-based AR alteration assessment
(amplifications, mutations, expression, splice variant
expression) has no clear clinical utility.
AR amplification and ARv7 expression are prog-
nostic in CRPC; emerging evidence suggests that ARv7
and AR amplification may be predictive, however, the
evidence is not yet sufficient to justify systematic ARv7 or
AR amplification testing.
Diagnostic Biomarkers
Diagnostic biomarkers are the most familiar to
pathologists and are most commonly deployed to assist in
the initial diagnosis of prostate cancer on core biopsy
samples. Tissue-based diagnostic biomarkers utilized in
this context include IHC stains for basal-cell markers and
have been reviewed elsewhere.140 In the last decade, sev-
eral newer tissue-based and urine-based markers have also
been introduced to assist with risk stratification in the
setting of a negative biopsy.141 Here, we will focus ex-
clusively on molecular markers to assist in the histologic
classification of prostate tumors at diagnosis, specifically
in the setting of NE differentiation which may function as
a predictive biomarker of response to AR-targeted therapy
in the primary and, more commonly, metastatic settings.
NEUROENDOCRINE PROSTATE CANCER
Background
The diagnosis of small cell or neuroendocrine pros-
tate cancer (NEPC) is rare in clinically localized disease
but frequently associated with poor outcomes.142 In ad-
vanced CRPC, small cell or NE morphology is observed
in around 10% of cases that have undergone biopsy120,143
and may develop as a form of linage plasticity enabling
resistance to AR-targeted therapies. The clinical median
survival for men with metastatic NEPC is poor with a
median 7 months survival.144 Though no large trials have
been conducted, in their pure form, these tumors generally
respond poorly to AR-targeted therapies leaving clinicians
with limited treatment options that include platinum
chemotherapy or, in the setting of clinical trials, newer
targeted therapies. Since this diagnosis will dramatically
change treatment strategies in the CRPC setting, accurate
pathologic diagnosis is critical.
A major challenge for practicing pathologists is the
accurate classification of CRPC given the lack of experi-
ence by most pathologists with this disease state and the
lack of clarity regarding how to integrate new molecular
findings. In its most classical form, small cell NEPC may
be recognized by classic morphologic features, including
sparse cytoplasm, small and often overlapping nuclei, and
the absence of prominent nucleoli. The chromatin is de-
scribed as “salt and pepper” in appearance. However there
is increasing recognition of a wide spectrum of NE dif-
ferentiation present in primary tumors, and particularly in
CRPC, this may present a diagnostic dilemma for the
practicing pathologist and necessitate the use of molecular
biomarkers145 (Fig. 4).
Evidence
The most recent 2016 WHO classification delineates 5
manifestations of NE differentiation in prostate cancer
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(Table 2).146 To better represent the observed spectrum,
other authors have recently added “mixed adenocarcinoma
and neuroendocrine carcinoma” and “amphicrine carci-
noma”.145,147 Morphologic classification of small cell
NEPC has historically been assisted by application of NE IHC
markers, such as chromogranin, synaptophysin, and CD56,
however, it is recognized that these markers individually are not
highly sensitive for small cell NEPC.142 More importantly, NE
markers are not specific for small cell NEPC and may be
expressed, at least focally, in a large proportion of usual-
type adenocarcinomas and have limited prognostic value in
the primary setting.148,149 Genomically, similar to its lung
counterpart, NEPC has an increased frequency of RB1 and
TP53 inactivation.120,150,151 However, these alterations are not
specific to NEPC and can be observed in usual-type
adenocarcinoma, particularly in the CRPC setting.120 Finally,
AR expression and signaling may be absent or low based on
IHC or gene expression in small cell NEPC, however, this
finding is also not specific for small cell NEPC (can be seen in
AR-independent, non-NEPC) and is also insensitive for small
cell NEPC as some subsets of cases may express AR.152
Recently, precision oncology studies have focused on
molecular and pathology alterations seen during the course of
androgen deprivation therapy.120,143 One recent study looking
at 444 CPRC cases treated with standard-of-care AR signaling-
targeted therapies demonstrated a range of histologies, includ-
ing 10% with NE features.120 Even with more extensive
genomic profiling, the overlap between morphologic NE fea-
tures and molecular alterations at the gene transcript or DNA
level was good but remained imperfect. CRPC tumors, which
would be classified as adenocarcinoma without NE features,
may display NE molecular features in some instances. This
observation may reflect a type of resistance also seen in epi-
dermal growth factor receptor-mutant non–small lung cancers
that undergo lineage plasticity towards small cell carcinoma
during the course of targeted therapy.153 Similar to lung tu-
mors, this change from adenocarcinoma to small cell NEPC
roughly parallels the lack of response to AR signaling in-
hibitors. From a clinical perspective, accurate classification of
these tumors is extremely important given the variety of
therapies available today for men with advanced prostate
cancer. Ultimately, dedicated, biomarker-driven clinical trials
must occur to better define the most clinically relevant bio-
markers of NEPC.
Discussion and Recommendations for NEPC
Markers
For clinically localized prostate cancer, focal NE
differentiation does not clearly impact biological behavior.
For advanced CRPC, we still need to define the molecular
and morphologic features that are predictive of a lack of
response to AR signaling-targeted therapy. Though mo-
FIGURE 4. Brain metastasis with overlapping features between small cell NE carcinoma and conventional acinar adenocarcinoma.
A, Two distinct adjacent areas with NE features on left and adenocarcinoma on the right. B, PSA positivity in both components. C
and D, Lack of expression of NE markers synaptophysin and chromogranin-A, respectively. H&E indicates hematoxylin and eosin.
TABLE 2. 2016 WHO Genitourinary Neuroendocrine Tumor
Classification
2016 WHO Genitourinary Tumor Classification146
NE cells in usual prostate cancer
Adenocarcinoma with Paneth cell-like NE differentiation
Well-differentiated NE tumor (carcinoid)
Small cell NE carcinoma
Large cell NE carcinoma
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lecular markers such as TP53 and RB1 inactivation or AR
expression may be helpful, they are not sensitive or specific
on their own and <10% of survey respondents endorsed
using these markers.
The current recommendations of the Working Group
are the following:
 For clinically localized prostate cancer, unless there are
clear morphologic NE features, immunostaining for
NE expression (eg, synaptophysin, chromogranin, or
CD56) is not recommended.
 Given its clinical implications, the term NE differ-
entiation is best reserved for high-grade cancers and not
usual-type adenocarcinomas or well-differentiated NE
tumors.
 Advanced metastatic CRPC may manifest a range of
morphologic features of NE differentiation and a
combination of molecular evaluation and morphologic
features may be required in future definitions of CRPC,
guided by biomarker-driven clinical trials.
CONCLUSIONS
Only a few pathologists are applying molecular
markers in prostate cancer in routine practice due to in-
sufficient evidence, lack of standardization, and the com-
plexity of the diverse disease stages, treatment modalities
and clinical endpoints. However, Ki-67 and PTEN are
emerging as potentially useful and widely available prog-
nostic markers to support treatment decisions at an early
stage. Similarly, mRNA-based commercial genomic sig-
natures can help stratifying the risk of progression in in-
dividual patients, although more studies are needed before
the widespread use of prognostic markers can be recom-
mended. There has been considerable progress of pre-
dictive marker analysis in poorly differentiated and/or
clinically advanced and CRPC, where markers of DNA
repair deficiency (eg, BRCA1/2 mutation and MMR de-
fects) provide new opportunities for personalized treat-
ment with PARP inhibitors and/or immunotherapy.
Moreover, a better understanding of enhanced AR sig-
naling (eg, AR amplification and ARV7 expression) and
NE transdifferentiation as mechanisms of castration re-
sistance can impact patient management.
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